Clinigen Group PLC Company Profile (LON:CLIN)

About Clinigen Group PLC (LON:CLIN)

Clinigen Group PLC logoClinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:CLIN
  • CUSIP: N/A
  • Web:
  • Market Cap: £1.3 billion
  • Outstanding Shares: 115,099,000
Average Prices:
  • 50 Day Moving Avg: GBX 1,107.56
  • 200 Day Moving Avg: GBX 964.27
  • 52 Week Range: GBX 695 - GBX 1,175
  • Trailing P/E Ratio: 352.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £302.3 million
  • Price / Sales: 4.29
  • Book Value: GBX 2.16 per share
  • Price / Book: 5.22
  • EBITDA: £61.3 million
  • Net Margins: 0.70%
  • Return on Equity: 0.98%
  • Return on Assets: 0.53%
  • Average Volume: 433,943 shs.

Frequently Asked Questions for Clinigen Group PLC (LON:CLIN)

What is Clinigen Group PLC's stock symbol?

Clinigen Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How often does Clinigen Group PLC pay dividends? What is the dividend yield for Clinigen Group PLC?

Clinigen Group PLC declared a dividend on Thursday, September 28th. Stockholders of record on Thursday, November 9th will be paid a dividend of GBX 3.40 per share on Friday, December 1st. This represents a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, November 9th. This is an increase from Clinigen Group PLC's previous dividend of $1.60. The official announcement can be viewed at this link. View Clinigen Group PLC's Dividend History.

How were Clinigen Group PLC's earnings last quarter?

Clinigen Group PLC (LON:CLIN) announced its quarterly earnings data on Thursday, September, 28th. The company reported $41.80 earnings per share for the quarter, beating the consensus estimate of $41.20 by $0.60. The business had revenue of $302.30 million for the quarter. Clinigen Group PLC had a return on equity of 0.98% and a net margin of 0.70%. View Clinigen Group PLC's Earnings History.

Where is Clinigen Group PLC's stock going? Where will Clinigen Group PLC's stock price be in 2017?

4 brokerages have issued 1 year target prices for Clinigen Group PLC's shares. Their predictions range from GBX 895 to GBX 1,350. On average, they anticipate Clinigen Group PLC's stock price to reach GBX 1,078.75 in the next twelve months. View Analyst Ratings for Clinigen Group PLC.

Who are some of Clinigen Group PLC's key competitors?

Who are Clinigen Group PLC's key executives?

Clinigen Group PLC's management team includes the folowing people:

  • Shaun Edward Chilton, Chief Executive Officer, Director
  • Martin James Abell, Chief Financial Officer - Elect, Director
  • Peter Vance Allen, Independent Non-Executive Chairman of the Board
  • John Bacon, Non-Executive Director
  • Peter Lutz George, Non-Executive Director
  • John Hartup, Independent Non-Executive Director
  • Ian J. Nicholson, Independent Non-Executive Director

How do I buy Clinigen Group PLC stock?

Shares of Clinigen Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group PLC's stock price today?

One share of Clinigen Group PLC stock can currently be purchased for approximately GBX 1,128.

MarketBeat Community Rating for Clinigen Group PLC (LON CLIN)
Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  308
MarketBeat's community ratings are surveys of what our community members think about Clinigen Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Clinigen Group PLC (LON:CLIN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: GBX 1,078.75
Consensus Price Target History for Clinigen Group PLC (LON:CLIN)
Price Target History for Clinigen Group PLC (LON:CLIN)
Analysts' Ratings History for Clinigen Group PLC (LON:CLIN)
DateFirmActionRatingPrice TargetDetails
10/10/2017Peel HuntUpgradeBuyGBX 1,200 -> GBX 1,350View Rating Details
7/18/2017Numis Securities LtdDowngradeAddGBX 1,100View Rating Details
5/22/2017Stifel NicolausReiterated RatingBuyGBX 970View Rating Details
4/13/2017N+1 SingerReiterated RatingBuyGBX 895View Rating Details
1/20/2016Royal Bank Of CanadaLower Price TargetOutperformGBX 770 -> GBX 750View Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Clinigen Group PLC (LON:CLIN)
Earnings by Quarter for Clinigen Group PLC (LON:CLIN)
Earnings History by Quarter for Clinigen Group PLC (LON CLIN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/28/2017Y 2017GBX 41.20GBX 41.80£302.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clinigen Group PLC (LON:CLIN)

No earnings estimates for this company have been tracked by


Dividend History by Quarter for Clinigen Group PLC (LON CLIN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/28/2017GBX 3.400.32%11/9/201711/9/201712/1/2017
3/15/2017GBX 1.600.2%3/23/20173/23/20174/13/2017
9/28/2016GBX 2.700.38%11/3/201611/3/201611/25/2016
3/2/2016GBX 1.300.2%3/17/20163/17/20164/8/2016
9/22/2015GBX 2.300.32%10/15/201510/15/201511/6/2015
9/24/2014GBX 2.100.46%10/16/201410/16/201411/7/2014
2/26/2014GBX 10.19%3/5/20143/5/20143/28/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Clinigen Group PLC (LON:CLIN)
Insider Trades by Quarter for Clinigen Group PLC (LON:CLIN)
Insider Trades by Quarter for Clinigen Group PLC (LON:CLIN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017Shaun Edward ChiltonInsiderSell100,000GBX 1,150£1,150,000
10/2/2017John BaconInsiderSell250,000GBX 1,093£2,732,500
6/28/2017John BaconInsiderSell200,000GBX 843£1,686,000
6/22/2017Peter Georgeformer CEOSell500,000GBX 875£4,375,000
11/11/2016John BaconInsiderSell200,000GBX 717£1,434,000
10/18/2016Shaun Edward ChiltonInsiderSell97,246GBX 750£729,345
5/16/2016Abell,MartinInsiderBuy11,296GBX 518£58,513.28
10/7/2015Edward Chilton,ShaunInsiderSell412,778GBX 685£2,827,529.30
6/3/2015John HartupInsiderSell23,934GBX 644£154,134.96
(Data available from 1/1/2013 forward)


Headline Trends for Clinigen Group PLC (LON:CLIN)
Latest Headlines for Clinigen Group PLC (LON:CLIN)
Loading headlines, please wait.


Social activity is not available for this stock.


Clinigen Group PLC (CLIN) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.